BACKGROUND: Gemcitabine (2', 2'-difluorodeoxycytidine; dFdC) an anticancer agent with activity in preclinical models, was felt to be a promising new chemotherapy drug which warranted testing in patients with advanced renal cell carcinoma. METHODS: Eighteen patients with histologically proven metastatic or locally recurrent renal cell carcinoma and bidimensionally measurable disease were accrued to a phase II study of gemcitabine administered intravenously on days 1, 8 and 15 of a 28 day treatment cycle. Initial doses of gemcitabine were 800 mg/m2; doses in subsequent cycles were escalated to a maximum of 1250 mg/m2, toxicity permitting. RESULTS: One partial response was seen for a response rate of 6%. Hematologic toxicity was not severe with this dosing schedule; however, two patients developed dyspnea with bronchospasm after repeated injections of drug. CONCLUSIONS: The dose and schedule of gemcitabine employed results in only a modest response rate in patients with advanced renal carcinoma. Investigators should be aware of the possibility of dyspnea and bronchospasm developing shortly after gemcitabine administration.
BACKGROUND:Gemcitabine (2', 2'-difluorodeoxycytidine; dFdC) an anticancer agent with activity in preclinical models, was felt to be a promising new chemotherapy drug which warranted testing in patients with advanced renal cell carcinoma. METHODS: Eighteen patients with histologically proven metastatic or locally recurrent renal cell carcinoma and bidimensionally measurable disease were accrued to a phase II study of gemcitabine administered intravenously on days 1, 8 and 15 of a 28 day treatment cycle. Initial doses of gemcitabine were 800 mg/m2; doses in subsequent cycles were escalated to a maximum of 1250 mg/m2, toxicity permitting. RESULTS: One partial response was seen for a response rate of 6%. Hematologic toxicity was not severe with this dosing schedule; however, two patients developed dyspnea with bronchospasm after repeated injections of drug. CONCLUSIONS: The dose and schedule of gemcitabine employed results in only a modest response rate in patients with advanced renal carcinoma. Investigators should be aware of the possibility of dyspnea and bronchospasm developing shortly after gemcitabine administration.
Authors: Stephen L Richey; Pheroze Tamboli; Chaan S Ng; E Lin; Zita D Lim; John C Araujo; Eric Jonasch; Padmanee Sharma; Lance C Pagliaro; Nizar M Tannir Journal: Am J Clin Oncol Date: 2013-10 Impact factor: 2.339
Authors: Peter J Van Veldhuizen; Michael Hussey; Primo N Lara; Philip C Mack; Regina Gandour-Edwards; Joseph I Clark; Marianne K Lange; David E Crawford Journal: Am J Clin Oncol Date: 2009-10 Impact factor: 2.339
Authors: Nizar M Tannir; Peter F Thall; Chaan S Ng; Xuemei Wang; Leiko Wooten; Arlene Siefker-Radtke; Paul Mathew; Lance Pagliaro; Christopher Wood; Eric Jonasch Journal: J Urol Date: 2008-07-17 Impact factor: 7.450